Top California Biotech Startups (578)
Tahoe Therapeutics (formerly Vevo Therapeutics) is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and...
ClearNote Health – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives. We focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. We apply our proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer...
Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The people at Pulse Biosciences are...
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and...
Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers...
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows...
Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases.
A new ecosystem for scientific progress. Arcadia Science is pushing the boundaries of open science and innovating at every step in the research, development, and commercialization process.
Stop wresting with cloud infrastructure and broken informatics tools. Start discovering biological insights today.
We help scientists solve disease and extend healthspan by building tools that simplify R&D, simulate biology, and untangle the complexity of life. Streamline computational analysis today. Simulate biology tomorrow.
For two hundred years vaccines have been administered by intramuscular injection. Vaxart’s oral vaccine pills may change everything. Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including the mouth, the nose and the gut. They are designed to trigger strong IgA and T-cell responses to repel and overwhelm...
Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. Our Founders and members of the Board are a group of esteemed, world-class scientists from the University of California,...
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’...
We are building reversible cryopreservation technology to solve the organ procurement and matching problem. Cryopreservation is already essential to modern medicine — powering IVF and life-saving stem cell therapies. Now, we’re extending this technology to whole human organs — transforming hours of viability into weeks, or months, however long is necessary — so that no donated organ is lost to logistics,...
Orchestra helps life sciences companies plan, manage, and execute their drug development programs.
Zack Abbott, PhD microbiologist, founded ZBiotics because of the potential genetically engineered probiotics have to improve daily living. Our first product is a probiotic that helps you feel better the day after drinking alcohol. ZBiotics is leveraging its patented technology to create a whole new category of products that help our bodies deal with whatever modern life throws our way....
Karius is a clinical metagenomics company focused on elevating patient care through microbial insights. We are committed to advancing diagnostic science and technology to optimize the diagnosis and treatment of infectious diseases. Through the use of genomics and AI, we are driven to improve the diagnostic landscape for infectious diseases. Karius delivers unprecedented diagnostic insight, detecting microbial cell-free DNA circulating...
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune...
